Borderline-low hemoglobin levels linked to increased mortality
1. In this prospective cohort study, mortality risk was higher among participants with hemoglobin concentrations below, 0 to 1 g/dL...
Hematology
N-methylaniline exposure identified as likely cause of methemoglobinemia during maritime migration
1. In this case series of severe acquired methemoglobinemia among migrants to Italy, prolonged skin exposure to fuel-contaminated seawater was...
Azacitidine–venetoclax improved event-free survival in induction-eligible AML
1. In this randomized phase 2 trial involving previously untreated adults with acute myeloid leukemia, azacitidine–venetoclax improved event-free survival compared...
![CRISPR-mediated gene activation rescues obesity caused by haploinsufficiency [PreClinical]](https://www.2minutemedicine.com/wp-content/uploads/2019/03/CRISPR-350x250.jpg)
Single-dose CRISPR therapy reduces hereditary angioedema attacks
1. In this phase 3 randomized controlled trial, a single infusion of lonvoguran ziclumeran reduced hereditary angioedema attacks by 87%...
Antithrombotic agents may be effective in preventing migraine in patients with patent foramen ovale
1. The antithrombotic agents aspirin, clopidogrel, and rivaroxaban were non-inferior to metoprolol for responder rate in participants with patent foramen...
Hematologic inflammatory indices may predict prognosis in younger patients with COVID-19 but not older patients
1. Hematologic inflammatory indices in emergency department patients with COVID-19 showed an age-dependent prognostic performance for 30-day mortality, with systemic...
Activated factor VIII-mimetic prophylaxis associated with reduced bleeding in hemophilia A
1. In adolescents and adults with hemophilia A, subcutaneous Mim8 prophylaxis reduced treated bleeding events versus on-demand therapy and versus...
Mezagitimab appears safe and potentially effective for persistent immune thrombocytopenia
1. In this phase 2 randomized controlled trial, weekly subcutaneous mezagitimab was well-tolerated and associated with symptomatic improvement among patients...
FDA grants priority review for iberdomide-based myeloma regimen
1. The FDA has granted priority review for iberdomide, a first-in-class oral CELMoD designed to degrade transcription factors more effectively...
Penpulimab and lenalidomide in combination with standard of care chemoimmunotherapy demonstrates promising safety and efficacy in diffuse large B-cell lymphoma
1. Penpulimab and lenalidomide in combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx regimen) is safe, tolerable, and shows antitumour activity...
